CAS 68392-35-8|(E/Z)-4-hydroxy Tamoxifen
Introduction：Basic information about CAS 68392-35-8|(E/Z)-4-hydroxy Tamoxifen, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | (E/Z)-4-hydroxy Tamoxifen | ||
|---|---|---|---|
| CAS Number | 68392-35-8 | Molecular Weight | 387.51400 |
| Density | 1.092 | Boiling Point | / |
| Molecular Formula | C26H29NO2 | Melting Point | 135-144°C |
| MSDS | ChineseUSA | Flash Point | / |
| Symbol | GHS07, GHS08 | Signal Word | Warning |
Names
| Name | Afimoxifene |
|---|---|
| Synonym | More Synonyms |
(E/Z)-4-hydroxy Tamoxifen BiologicalActivity
| Description | (E/Z)-4-Hydroxytamoxifen is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is an estrogen receptor modulator. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>Estrogen Receptor/ERRResearch Areas >>Cancer |
| Target | Estrogen receptor |
Chemical & Physical Properties
| Density | 1.092 |
|---|---|
| Melting Point | 135-144°C |
| Molecular Formula | C26H29NO2 |
| Molecular Weight | 387.51400 |
| Exact Mass | 387.22000 |
| PSA | 32.70000 |
| LogP | 5.70170 |
| Appearance of Characters | white to off-white |
| InChIKey | TXUZVZSFRXZGTL-UHFFFAOYSA-N |
| SMILES | CCC(=C(c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1 |
| Storage condition | Refrigerator |
| Water Solubility | methanol: soluble10mg/mL |
Safety Information
| Symbol | GHS07, GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H312-H332-H361 |
| Precautionary Statements | P280 |
| Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | Xn |
| Risk Phrases | 63-20/21/22 |
| Safety Phrases | 22-23-36 |
| RIDADR | NONH for all modes of transport |
| RTECS | SL1210000 |
Articles179
More Articles| Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 17 , 26, (2015) The emergence of hormone therapy resistance, despite continued expression of the estrogen receptor (ER), is a major challenge to curing breast cancer. Recent clinical studies suggest that epigenetic m... | |
| Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86. BMC Cancer 14 , 853, (2014) The RET tyrosine kinase receptor has emerged as a target in thyroid and endocrine resistant breast cancer. We previously reported the synthesis of kinase inhibitors with potent activity against RET. H... | |
| Pharmacological inhibition of dynamin II reduces constitutive protein secretion from primary human macrophages. PLoS ONE 9(10) , e111186, (2014) Dynamins are fission proteins that mediate endocytic and exocytic membrane events and are pharmacological therapeutic targets. These studies investigate whether dynamin II regulates constitutive prote... |
Synonyms
| Propiophenone,4'-[2-(diethylamino)ethoxy]-,hydrochloride |
| 1-[4-(2-Diaethylamino-aethoxy)-phenyl]-propan-1-on,Hydrochlorid |
| 1-[4-(2-diethylaminoethyloxy)phenyl]propan-1-one hydrochloride |
| 4-hydroxytamoxifene |
| 1-[4-(2-dimethylaminoethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbut-1-ene |
| (E,Z)-4-hydroxytamoxifen |
| 1-[4-(2-diethylamino-ethoxy)-phenyl]-propan-1-one,hydrochloride |
